Euronext Amsterdam

BenevolentAI Appoints New Chief Technology Officer

Retrieved on: 
Wednesday, March 20, 2024
Science, Biotechnology, Research, Pharmaceutical, Finance, Health, Health Technology, Professional Services, Machine learning, EBI, Elsevier, Bioinformatics, Drug discovery, University of Edinburgh, Artificial intelligence, Benevolence, AI, Doctor of Philosophy, Engineering, BAI, Family, Euronext Amsterdam, European

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces that the current Chief Technology Officer (CTO), Dr. Daniel Neil, is leaving the Company at the beginning of April after 7 years at BenevolentAI to relocate to be nearer his family.
  • The Company is pleased to announce the appointment of Dr. James Malone as BenevolentAI’s new Chief Technology Officer.
  • As Chief Technology Officer at SciBite, James helped build software using ontologies, machine learning and knowledge graphs to analyse scientific data.
  • Specifically, his experience in building technology to support R&D within biotech will help with the continuing development of the BenevolentAI PlatformTM, which is critical for us to deliver cutting edge AI-driven drug discovery.”
    Dr. James Malone, incoming Chief Technology Officer, commented: “I’m excited to join the leadership team at BenevolentAI.

BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice

Retrieved on: 
Wednesday, March 20, 2024
Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Account, BAI, Euronext Amsterdam, Remuneration, Documentation, AGM, Annual report, Policy

BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”).

Key Points: 
  • BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces the publication of its Annual Report and Accounts for the year ended 31 December 2023 (the “2023 Annual Report”) and the convening notice for its annual general meeting to be held on 2 May 2024 at 14:00 CEST at 2, place Winston Churchill, L-1340 Luxembourg (the “2024 AGM”) (the “2024 AGM Notice”).
  • The 2023 Annual Report, the 2024 AGM Notice, the amended Remuneration Policy of the Company, the proxy form and any other meeting documentation are available on the Company’s website ( www.benevolent.com/investors/general-meetings/ ) and at the Company’s registered office.
  • The shareholders entitled to participate and vote at the 2024 AGM will be those who are shareholders on the record date of 18 April 2024 at 24:00 (midnight) CEST.

BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023

Retrieved on: 
Thursday, March 14, 2024
Biotechnology, Pharmaceutical, Finance, Health, Artificial Intelligence, Health Technology, Professional Services, Technology, Knowledge, PDE10, Ulcerative colitis, Neurology, AstraZeneca, Atopic dermatitis, ALS, Glioblastoma, Drug discovery, Benevolence, Patient, GBM, Cash, UC, Chairperson, Research, Merck, IND, SBP, BAI, Retinoic acid receptor alpha, Safety, Euronext Amsterdam, Pharmaceutical industry

BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.

Key Points: 
  • BenevolentAI (“BenevolentAI”, “the Company” or “the Group”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma drug discovery, today announces its unaudited preliminary results for the twelve months ended 31 December 2023.
  • Dr. Joerg Moeller, Chief Executive Officer (CEO) of BenevolentAI, said:
    "I am delighted to present my inaugural set of financial results as the CEO of BenevolentAI.
  • I look forward to working closely with them, and our partners, to make a lasting impact on the lives of patients worldwide."
  • Cash, cash equivalents and short-term deposits position of £72.9 million at 31 December 2023 (31 December 2022: £130.2 million), compared with £84.3 million at 30 June 2023.

Arkon Energy Places Firm Purchase Order for 27,700 New-Generation Mining Machines

Retrieved on: 
Tuesday, April 2, 2024
Bitcoin, Letter, S21, Heel, Arkon, T21, Miner, Euronext Amsterdam, Cryptocurrency

HANNIBAL, Ohio, April 2, 2024 /PRNewswire/ -- Arkon Energy US Holdco LLC ("Arkon" or the "Company") announces that it has placed a firm purchase order with Bitmain Development Pte.

Key Points: 
  • HANNIBAL, Ohio, April 2, 2024 /PRNewswire/ -- Arkon Energy US Holdco LLC ("Arkon" or the "Company") announces that it has placed a firm purchase order with Bitmain Development Pte.
  • Ltd ("Bitmain") to purchase 27,700 new-generation Bitcoin mining machines, or the equivalent of approximately 6 exahashes per second ("EH/s").
  • The purchase order includes 14,200 T21 machines and 13,500 S21 machines with deliveries to be scheduled beginning in June 2024.
  • The parties intend to negotiate definitive agreements with respect to the purchase order in the coming days.

VEON to Hold Capital Markets Day on June 6, 2024

Retrieved on: 
Monday, March 11, 2024
Euronext Amsterdam, Capital market, VEON

VEON to Hold Capital Markets Day on June 6, 2024

Key Points: 
  • VEON to Hold Capital Markets Day on June 6, 2024
    Amsterdam, 11 March 2024: VEON (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that the company will hold a Capital Markets Day on Thursday, June 6, 2024.
  • In order to indicate your interest in VEON’s 2024 Capital Markets Day, please register here: https://brookepeeladvisors.eventogy.com/c/veoncapitalmarketsday2024 .
  • This event is reserved for investors and analysts only.

MSCI upgrades VEON to 'AA' ESG Rating

Retrieved on: 
Monday, March 4, 2024
ESG, AA, Euronext Amsterdam, Certification, VEON

Amsterdam, 4 March 2024: VEON (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that, MSCI has raised the Company’s Environmental, Social, and Governance (ESG) rating to 'AA' from 'A'.

Key Points: 
  • Amsterdam, 4 March 2024: VEON (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that, MSCI has raised the Company’s Environmental, Social, and Governance (ESG) rating to 'AA' from 'A'.
  • This upgrade positions VEON within the ‘Leaders’ category amongst the 131 telecommunication services companies evaluated by MSCI, demonstrating our commitment to sustainable and ethical business operations.
  • The ESG rating agency also named VEON’s exit from Russia as a factor contributing to the rating upgrade.
  • For further details on VEON and our ESG practices, please visit our website at https://www.veon.com/we-are-veon/sustainability .

VEON announces the issuance of previously authorized shares representing approximately 4.99% of total share capital

Retrieved on: 
Friday, March 1, 2024
USD, Growth, Euronext Amsterdam, LetterOne, VEON, Security (finance)

As a result of the issuance, VEON will have 1,849,190,667 issued and outstanding ordinary shares.

Key Points: 
  • As a result of the issuance, VEON will have 1,849,190,667 issued and outstanding ordinary shares.
  • The issuance of the ordinary shares in accordance with bye-law 3.1 of the VEON bye-laws represents approximately 4.99% of VEON's authorised ordinary shares.
  • The shares will be initially issued to VEON Holdings BV (and in accordance with Bermuda law are considered fully issued and outstanding shares).
  • The ordinary shares will be issued at a price of USD 0.001 per share, which is equal to the nominal value of VEON's ordinary shares.

VEON’s Kyivstar Awarded “Best Mobile Innovation Supporting Emergency or Humanitarian Situations” at GLOMOs

Retrieved on: 
Thursday, February 29, 2024
Volodymyr, Investment, Mobile World Congress, Euronext Amsterdam, VEON

Kyivstar CTO Volodymyr Lutchenko accepted the award in a ceremony organized as a part of the MWC24, Mobile World Congress in Barcelona.

Key Points: 
  • Kyivstar CTO Volodymyr Lutchenko accepted the award in a ceremony organized as a part of the MWC24, Mobile World Congress in Barcelona.
  • “It is an honour to be recognized with a GLOMO for the Kyivstar team’s tremendous work in providing a lifeline to Ukraine.
  • Kyivstar is the largest telecoms operator in Ukraine with 24 million mobile subscribers and over 1.1 million home internet subscribers.
  • VEON and Kyivstar have committed 600m USD in investments over the next three years to support Ukraine’s reconstruction and recovery.

Pharming Group to report fourth quarter and full year 2023 financial results on March 14

Retrieved on: 
Thursday, February 29, 2024
EDT, PIN, Euronext Amsterdam

Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.

Key Points: 
  • Leiden, The Netherlands, February 29, 2024: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) fourth quarter and full year 2023 financial results, for the period ended December 31, on Thursday, March 14, 2024.
  • Pharming will host a presentation for analysts and investors at 13:30 CET/08:30 am EDT on March 14, 2024.
  • To participate in the conference call, please register in advance using the link below.
  • Once registered, dial-in information and a unique PIN will be provided, allowing access to the call.

VEON launches ROX, its digital-first brand in Pakistan

Retrieved on: 
Tuesday, February 27, 2024
OQ, Tamasha, Maus, GameNOW, Euronext Amsterdam, ROX, IZI, VEON

MWC24 Barcelona, 27 February 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that Jazz, its digital operator in Pakistan, is launching ROX, a new mobile service brand to serve the digital natives of the country with an integrated lifestyle experience.

Key Points: 
  • MWC24 Barcelona, 27 February 2024: VEON Ltd. (NASDAQ: VEON, Euronext Amsterdam: VEON), a global digital operator that provides converged connectivity and online services, announces that Jazz, its digital operator in Pakistan, is launching ROX, a new mobile service brand to serve the digital natives of the country with an integrated lifestyle experience.
  • ROX is designed to appeal to the digital-first generation of Pakistan and provides a range of digital lifestyle services through a dedicated mobile app.
  • "In Pakistan, with 64% of the population under the age of 30, there is a significant demand for digital-first experiences.
  • In Uzbekistan, the OQ was launched in October 2023 and had already gained 177 thousand MAUs by December 31st.